Literature DB >> 3872312

Interleukin-2 production by persons with the generalized lymphadenopathy syndrome or the acquired immune deficiency syndrome.

C H Kirkpatrick, K C Davis, C R Horsburgh, D L Cohn, K Penley, F N Judson.   

Abstract

We measured production of interleukin-2 (IL-2) by phytohemagglutinin-stimulated peripheral blood mononuclear cells from 27 heterosexual persons, 43 asymptomatic homosexual men, 34 homosexual men with generalized lymphadenopathy syndrome (GLS), and 21 patients with acquired immune deficiency syndrome (AIDS). Asymptomatic heterosexual and homosexual subjects produced comparable amounts of IL-2, but 8 of 11 AIDS patients with opportunistic infections and two of three AIDS patients with both opportunistic infections and Kaposi's sarcoma failed to produce detectable amounts of IL-2; all seven AIDS patients with only Kaposi's sarcoma produced IL-2. The titer of IL-2 produced by the AIDS patients correlated with the percentage of helper T lymphocytes (Leu 3a+ cells) but not with the percentage of suppressor T lymphocytes (Leu 2a+ cells). This observation is interpreted as indicating that failure to produce IL-2 by AIDS patients is most likely due to depletion of IL-2-producing cells, although an abnormality of T-cell function has not been excluded. In addition, three of eight AIDS patients who did not produce IL-2 produced supernatants that inhibited growth of IL-2-dependent cells in the presence of IL-2. These observations suggest that measurement of endogenous IL-2 production may be important in selecting patients for therapy with IL-2.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Biology; Diseases; Examinations And Diagnoses; Hiv Infections; Immunity; Immunological Effects--changes; Laboratory Examinations And Diagnoses; Laboratory Procedures; Physiology; Viral Diseases

Mesh:

Substances:

Year:  1985        PMID: 3872312     DOI: 10.1007/bf00915166

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  30 in total

1.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

Review 2.  NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations.

Authors:  A S Fauci; A M Macher; D L Longo; H C Lane; A H Rook; H Masur; E P Gelmann
Journal:  Ann Intern Med       Date:  1984-01       Impact factor: 25.391

3.  Immunological studies of aging. Decreased production of and response to T cell growth factor by lymphocytes from aged humans.

Authors:  S Gillis; R Kozak; M Durante; M E Weksler
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

4.  Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome.

Authors:  B Safai; M G Sarngadharan; J E Groopman; K Arnett; M Popovic; A Sliski; J Schüpbach; R C Gallo
Journal:  Lancet       Date:  1984-06-30       Impact factor: 79.321

5.  Diminished interleukin-2 activity production in cancer patients bearing solid tumors and its relationship with natural killer cells.

Authors:  A Rey; B Klein; D Zagury; C Thierry; B Serrou
Journal:  Immunol Lett       Date:  1983-03       Impact factor: 3.685

6.  Quantitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders.

Authors:  J L Fahey; H Prince; M Weaver; J Groopman; B Visscher; K Schwartz; R Detels
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

7.  Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE).

Authors:  M Linker-Israeli; A C Bakke; R C Kitridou; S Gendler; S Gillis; D A Horwitz
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

8.  Human lymphocytes with either the OKT4 or OKT8 phenotype produce interleukin 2 in culture.

Authors:  T A Luger; J S Smolen; T M Chused; A D Steinberg; J J Oppenheim
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

9.  Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome.

Authors:  A H Rook; H Masur; H C Lane; W Frederick; T Kasahara; A M Macher; J Y Djeu; J F Manischewitz; L Jackson; A S Fauci; G V Quinnan
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

10.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  9 in total

1.  Casp8p41 expression in primary T cells induces a proinflammatory response.

Authors:  Julie A Taylor; Nathan W Cummins; Gary D Bren; Stacey A Rizza; Christopher P Kolbert; Marshall D Behrens; Keith L Knutson; Jane C Kahl; Yan W Asmann; Andrew D Badley
Journal:  AIDS       Date:  2010-06-01       Impact factor: 4.177

2.  Methionine-enkephalin as immunomodulator therapy in human immunodeficiency virus infections: clinical and immunological effects.

Authors:  K M Zunich; C H Kirkpatrick
Journal:  J Clin Immunol       Date:  1988-03       Impact factor: 8.317

3.  Effect of amino acid substitutions on calmodulin binding and cytolytic properties of the LLP-1 peptide segment of human immunodeficiency virus type 1 transmembrane protein.

Authors:  S B Tencza; M A Miller; K Islam; T A Mietzner; R C Montelaro
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

4.  Altered immunity in hemophilia correlates with the presence of antibody to human T-cell lymphotropic virus type III (HTLV-III).

Authors:  C R Horsburgh; K C Davis; U Hasiba; S H Weiss; J J Goedert; P Sarin; C H Kirkpatrick
Journal:  J Clin Immunol       Date:  1986-01       Impact factor: 8.317

5.  Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo.

Authors:  S K Sambhi; M R Kohonen-Corish; I A Ramshaw
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

6.  Increased interleukin-2 receptor expression after mitogen stimulation on CD4- and CD8-positive lymphocytes and decreased interleukin-2 production in HTLV-III antibody-positive symptomatic individuals.

Authors:  P C Creemers; M O'Shaughnessy; W J Boyko
Journal:  Immunology       Date:  1986-12       Impact factor: 7.397

7.  Effect of 1,1-dimethylhydrazine on lymphoproliferation and interleukin 2 immunoregulatory function.

Authors:  R M Bauer; M J Tarr; R G Olsen
Journal:  Arch Environ Contam Toxicol       Date:  1990 Jan-Feb       Impact factor: 2.804

8.  Tumor necrosis factors alpha and beta in acquired immunodeficiency syndrome (AIDS) and aids-related complex.

Authors:  A J Ammann; M A Palladino; P Volberding; D Abrams; N L Martin; M Conant
Journal:  J Clin Immunol       Date:  1987-11       Impact factor: 8.317

Review 9.  Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?

Authors:  Guido Vanham; Ellen Van Gulck
Journal:  Retrovirology       Date:  2012-09-07       Impact factor: 4.602

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.